HBP1 Human Pre-designed siRNA Set A contains three designed siRNAs for HBP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HBpep-SA is a cell membrane-permeable peptide condensate that phase separates to form stable droplets at pH values below 6.5. HBpep-SA is able to directly and efficiently deliver a variety of macromolecules, ranging from therapeutic peptides as small as 726 Da to large enzymes as large as 430 kDa, and the loaded condensates remain stable under […]

HBpep-SA is a cell membrane-permeable peptide condensate that phase separates to form stable droplets at pH values below 6.5. HBpep-SA is able to directly and efficiently deliver a variety of macromolecules, ranging from therapeutic peptides as small as 726 Da to large enzymes as large as 430 kDa, and the loaded condensates remain stable under […]

HBpep-SP TFA is the TFA salt form of HBpep-SP (HY-P6021). HBpep-SP TFA is utilized for delivery and release of proteins, peptides and mRNA[1].

HBpep-SP TFA is the TFA salt form of HBpep-SP (HY-P6021). HBpep-SP TFA is utilized for delivery and release of proteins, peptides and mRNA[1].

HBpep-SP TFA is the TFA salt form of HBpep-SP (HY-P6021). HBpep-SP TFA is utilized for delivery and release of proteins, peptides and mRNA[1].

HBQ1 Human Pre-designed siRNA Set A contains three designed siRNAs for HBQ1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HBS1L Human Pre-designed siRNA Set A contains three designed siRNAs for HBS1L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HBT-Fl-BnB is a fluorescent probe for the ratiometric detection of ONOO– in vitro and in vivo. HBT-Fl-BnB consists of an HBT core with Fl groups at the ortho and para positions responding to the zwitterionic excited-state intramolecular proton-transfer (zwitterionic ESIPT) process and a boronic acid pinacol ester with dual roles that block the zwitterionic ESIPT […]

HBV-IN-44 (Compound (S)-2a) is a HBV inhibitor with a IC50 value of 23 nM for HbsAg. HBV-IN-44 is less toxic to the neurite growth of HT22 cells and DRG neurons in vitro[1].

HBV-IN-45 is a selective and orally active HBV capsid assembly modulator with an IC50 of 0.51 μM for HBcAg in HBC cells. HBV-IN-45 shows potent anti-HBV activities[1].

HBZ Human Pre-designed siRNA Set A contains three designed siRNAs for HBZ gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

hCAI/II-IN-8 (Compound 8) is a hydrazide derivative based on 4-hydroxybenzaldehyde. hCAI/II-IN-8 primarily targets human carbonic anhydrase isomerase I (hCA I) and II (hCA II) for inhibition (IC50 = 21.35 ± 0.39 nM (hCA I); 7.12 ± 0.12 nM (hCA II)). hCAI/II-IN-8 inhibits AChE and BChE as well(IC50 = 46.27 ±0.75 nM (AChE); 43.38 ± 0.83 […]

hCAII-IN-10 (compound 11d) is hCA II inhibitor with the IC50s of 14 nM and 29.2 μM for hCA II and hCA I, respectively. hCAII-IN-10 inhibits cell growth against HT-29 cells with the IC50 of 74 μM. hCAII-IN-10 shows strongly lowered intraocular pressure in the glaucomatous rabbit eye model[1].

hCAIX/XII-IN-10 (compound DK-8) is a carbonic anhydrase inhibitor. hCAIX/XII-IN-10 has potent inhibitory activity against tumor-associated membrane-bound isoforms hCA IX and XII, with Ki values of 32.5 nM and 29.2 nM[1].

hCAIX/XII-IN-11 (Compound 6c) is an inhibitor of hCA IX and hCA XII with a Ki value of 0.7 μM for both the isoforms. hCAIX/XII-IN-11 can be used for anticancer research[1].

HCAR1 Human Pre-designed siRNA Set A contains three designed siRNAs for HCAR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCAR2 Human Pre-designed siRNA Set A contains three designed siRNAs for HCAR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hcar2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hcar2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hcar2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hcar2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCAR3 Human Pre-designed siRNA Set A contains three designed siRNAs for HCAR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

hCAXII-IN-8 (compound 5r) is a potent carbonic anhydrase hCA XII inhibitor[1].

hCAXII-IN-9 (Compound 3I) is a selective inhibitor of hCAXII with Ki values of 28 nM, 7192.6 nM, 188.6 nM, and >100000 nM for hCAXII, hCAI, hCAII, and hCAIX, respectively. hCAXII-IN-9 can be utilized in antitumor research[1].

HCFC1 Human Pre-designed siRNA Set A contains three designed siRNAs for HCFC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCG22 Human Pre-designed siRNA Set A contains three designed siRNAs for HCG22 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCK Human Pre-designed siRNA Set A contains three designed siRNAs for HCK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCLS1 Human Pre-designed siRNA Set A contains three designed siRNAs for HCLS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCN1 Human Pre-designed siRNA Set A contains three designed siRNAs for HCN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCN2 Human Pre-designed siRNA Set A contains three designed siRNAs for HCN2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCN3 Human Pre-designed siRNA Set A contains three designed siRNAs for HCN3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCN4 Human Pre-designed siRNA Set A contains three designed siRNAs for HCN4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCRT Human Pre-designed siRNA Set A contains three designed siRNAs for HCRT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCRTR1 Human Pre-designed siRNA Set A contains three designed siRNAs for HCRTR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hcrtr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hcrtr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hcrtr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hcrtr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCRTR2 Human Pre-designed siRNA Set A contains three designed siRNAs for HCRTR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hcrtr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hcrtr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hcrtr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hcrtr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCST Human Pre-designed siRNA Set A contains three designed siRNAs for HCST gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HCY/BSA is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of HCY () and BSA. PCDs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases[1].

HDAC-IN-70 (compound 4c) is HDAC6 inhibitor with the IC50 values of 64.13 nM, 166 nM, 618 nM and 253 nM for HDAC6, HDAC1, HDAC2 and HDAC4, respectively. HDAC-IN-70 induces cell cycle arrest, apoptosis and necrotic. HDAC-IN-70 can be used for study of leukemia[1].

HDAC-IN-71 (Compound 17q) is a potent HDAC inhibitor with IC50 values of 12.6, 14.1, 20, 3, and 72 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC10, respectively. HDAC-IN-71 induces apoptosis and can be used in cancer research[1].

HDAC-MB a probe that is activated by HDAC6 and can detect and eliminate glioma cells through activation by HDAC6. HDAC-MB reveals antimetastatic and antiproliferative properties, inhibits glioma invasion and induces cellular apoptosis[1].

HDAC1 Human Pre-designed siRNA Set A contains three designed siRNAs for HDAC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hdac1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hdac1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hdac1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hdac1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HDAC1-IN-7 (compound 9) is potent HDAC1 inhibitor, with the IC50 of 0.957 mM[1].

HDAC10 Human Pre-designed siRNA Set A contains three designed siRNAs for HDAC10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hdac10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hdac10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.